Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. reports developments as a clinical-stage global biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. Company news commonly covers quarterly financial results, pipeline updates, clinical program strategy, data presentations and changes in research priorities across its investigational portfolio.
Recurring updates focus on casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer, and earlier inflammation programs such as AB102, an MRGPRX2 antagonist. Arcus also issues routine corporate announcements on employment inducement grants, investor conference participation and collaboration-related developments.
Arcus Biosciences (NYSE: RCUS) announced a clinical supply agreement with AVEO Oncology, an LG Chem company, to evaluate Arcus’s investigational HIF-2α inhibitor casdatifan (AB521) in combination with AVEO’s VEGFR TKI tivozanib (FOTIVDA) in advanced clear cell renal cell carcinoma (ccRCC).
The agreement supports a new randomized cohort within the ongoing ARC-20 platform study, comparing casdatifan plus tivozanib (1.34 mg) versus tivozanib (1.34 mg) alone in patients with advanced ccRCC previously treated with a HIF-2α inhibitor. AVEO will supply tivozanib, while Arcus will sponsor and conduct the study; each company retains development and commercial rights to its own compound. Enrollment for this cohort is expected to begin in the fourth quarter of 2026. Casdatifan is being developed as a potential backbone therapy across first- and second-line metastatic ccRCC settings, including the global Phase 3 PEAK-1 study of casdatifan plus cabozantinib versus cabozantinib alone.
Arcus Biosciences (NYSE: RCUS) and Summit Therapeutics (Nasdaq: SMMT) entered a clinical trial collaboration to evaluate Arcus’s HIF-2α inhibitor casdatifan (AB521) combined with Summit’s PD‑1/VEGF bispecific antibody ivonescimab in clear cell renal cell carcinoma, including first-line metastatic disease.
Arcus will sponsor and conduct a new combination cohort within its ARC‑20 platform study; Summit will supply ivonescimab. Both companies will share study costs and retain development and commercialization rights to their respective molecules. Initial data from this combination are expected by mid‑2027, adding to Arcus’s broader casdatifan program and Summit’s growing ivonescimab franchise.
Arcus Biosciences (NYSE:RCUS) will host a conference call and webcast on Wednesday, August 5, 2026 at 1:30 PM PT / 4:30 PM ET to discuss second-quarter 2026 financial results and pipeline updates. Investors can join via phone, online registration, or live webcast with a replay available.
Arcus Biosciences (NYSE:RCUS) announced new employment inducement equity awards granted by its board’s Compensation Committee. Five new employee stock options for a total of 16,060 shares were issued with an exercise price of $30.26, the July 8, 2026 closing price, plus 8,080 RSUs. These grants were made under the company’s 2020 Inducement Plan, adopted in January 2020 pursuant to the NYSE “inducement exception” under Rule 303A.08.
Arcus Biosciences (RCUS) reported Nature-published ARC-20 data on casdatifan, an investigational HIF-2a inhibitor for metastatic clear cell kidney cancer. In four monotherapy cohorts (n=121), casdatifan achieved 31% confirmed ORR and 12.2-month median PFS, with deeper serum EPO suppression correlating with higher response and longer PFS.
In the 100mg QD tablet cohort (n=31), confirmed ORR was 35%, 12‑month PFS was 60%, and later analysis showed 15.1‑month median PFS. According to Arcus, safety was acceptable, with anemia and hypoxia as main class-effect events and 9% treatment discontinuation due to TEAEs.
Arcus Biosciences (NYSE:RCUS) granted employment inducement equity awards to two new employees under its 2020 Inducement Plan. The grants include options to purchase 18,400 shares at an exercise price of $28.18 per share and 9,250 restricted stock units, using the NYSE inducement exception.
Arcus Biosciences (NYSE:RCUS) granted new employment inducement equity awards to one employee. The package includes options to purchase 2,850 shares of common stock at an exercise price of $23.32 per share and 1,450 restricted stock units, issued under the 2020 Inducement Plan pursuant to NYSE Rule 303A.08.
Arcus Biosciences (NYSE:RCUS) entered a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE:BMY) to evaluate casdatifan, an investigational HIF-2a inhibitor, in the Phase 1/2 ROSETTA RCC-208 trial for advanced renal cell carcinoma.
Casdatifan will be added as two new trial arms in combination with pumitamig, an investigational PD-L1/VEGF-A bispecific antibody. Each company keeps development and commercial rights, and the agreement is mutually non-exclusive.
Arcus Biosciences (NYSE:RCUS) announced participation in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL.
Its management will join a fireside chat on Tuesday, June 9, 2026 at 10:40 a.m. ET, with a live webcast and replay available via the company’s website.
Arcus Biosciences (NYSE:RCUS) reported first-quarter 2026 results and a pipeline update. Key items: $876M in cash and equivalents at March 31, 2026 with runway to at least H2 2028; expected year-end 2026 cash of ~$600M. Casdatifan development is prioritized with PEAK-1 enrollment and a planned 1L Phase 3 start by year-end 2026. AB102 (MRGPRX2 antagonist) is expected to enter the clinic in Q3 2026. PRISM-1 topline results for quemliclustat are expected in H1 2027. Net loss was $128M in Q1 2026; revenue guidance for 2026 is $50–65M.